Ramelteon demonstrates no abuse potential according to study results

Atlanta, GA, May 23, 2005 Results of a clinical study indicated that ramelteon, an investigational compound currently under review by the FDA for insomnia treatment, had no more potential for abuse than placebo in individuals with a history of polydrug abuse. These results, presented at the 2005 American Psychiatric Association Annual Meeting, showed that patients exhibited no abuse potential or behavioral impairment at up to 20 times the proposed therapeutic dose of ramelteon compared to placebo.

"In the treatment of insomnia, drug abuse potential is a significant concern to patients as well as to prescribing physicians," said Roland Griffiths, PhD, Professor in the departments of Psychiatry and Neuroscience, Johns Hopkins Bayview Medical Center, Baltimore, MD. "The chronic nature of some types of insomnia may necessitate treatment for an extended period, underscoring the need for sleep medications with little or no abuse potential."

It is estimated that 60 million Americans suffer from insomnia at least a few nights per week. Most currently prescribed sleep agents and some investigational drugs work by targeting gamma-aminobutyric acid (GABA) receptors, which are located throughout the brain. In pre-clinical studies, ramelteon has shown no affinity for GABA or opiate receptors.

Study Design

This study was a placebo-controlled, crossover clinical study of fourteen adults with a history of polydrug or multiple-drug abuse. These subjects were entered into a 7-day double-blind treatment period, comparing behavioral effects and abuse potential of ramelteon and triazolam, a benzodiazepine sedative-hypnotic.

During the treatment period, study medication was administered to patients in a randomly-assigned sequence and included:

  • ramelteon (16 mg, 80 mg, 160 mg);
  • triazolam (0.25 mg, 0.50 mg, 0.75 mg); and,
  • placebo.

Measures of "drug-liking," were assessed each day using questionnaires


Page: 1 2 3

Related medicine news :

1. New study finds that Ramelteon shows potential for circadian phase shifting
2. Energy Up demonstrates success as obesity intervention program for inner-city girls
3. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
4. New study demonstrates that Lubiprostone may improve symptom relief rates in adults with IBS-C
5. Research demonstrates link between domestic violence and asthma
6. New study demonstrates nicotines role in smoking behavior
7. Study demonstrates long-term durability of Plicator procedure
8. Circumcision for prevention of HIV: new analysis demonstrates cost-effectiveness
9. Canadian study demonstrates medical induction of labor increases risk of amniotic-fluid embolism
10. ACTOS (pioglitazone HCl) demonstrates significant improvements in cardiovascular outcomes
11. Study demonstrates successful HIV-prevention program for Latino youth

Post Your Comments:

(Date:7/7/2020)... ... July 07, 2020 , ... Great Point Partners (“GPP”) today announced that the ... appointed Rick Katz as Vice President of Business Development. , "After a comprehensive ... this leadership role for the organization," said Adam Elberg, chairman of the Spine & ...
(Date:7/4/2020)... ... 03, 2020 , ... MemoryCare.com , a comprehensive resource ... Memory Care Facilities in Charleston, South Carolina. The guide identifies 5 memory care ... According to the Alzheimer’s Association , 5.6 million people age 65 and ...
(Date:7/2/2020)... (PRWEB) , ... July 02, 2020 , ... Allegheny Health ... organization’s new Chief Medical Information Officer (CMIO), effective immediately. Dr. Lee succeeds Robert ... stay with AHN through the end of the year to help support a seamless ...
(Date:7/1/2020)... (PRWEB) , ... July 01, 2020 , ... ... specializing in the clinical development of psychedelics and analogues, announces its core executive ... experience in natural product drug discovery, novel formulations, and as distinguished researchers within ...
(Date:6/28/2020)... (PRWEB) , ... June 26, 2020 , ... ... whose mission is to provide high-quality, intensive education and training that prepares graduates ... Joyce Williams as new member of the Board of Trustees. , Ms. Williams ...
Breaking Medicine News(10 mins):
(Date:7/10/2020)... ... 10, 2020 , ... The Dolphin Company, the largest ... than 12 million guests, unveiled its new comprehensive plan of protocols and communication ... all facets of the operation, safety, and health addressing COVID-19. , Experts developed ...
(Date:7/10/2020)... FRANCISCO, Calif. (PRWEB) , ... ... ... Pharmaceutical Review , the leading review of business and technology for the ... cover the development and manufacturing of the highest quality pharmaceutical products. ...
(Date:7/7/2020)... , ... July 07, 2020 , ... To support those ... of Global Change (WGC), will be providing meals to the employees of Southern Nevada ... testing sites throughout Las Vegas on Wednesday, July 8th. , When asked why the ...
Breaking Medicine Technology:
Cached News: